Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

ALLO | Allogene Therapeutics Inc

Index	RUT	P/E	-	EPS (ttm)	-2.45	Insider Own	36.70%	Shs Outstand	144.44M	Perf Week	-13.15%
Market Cap	531.39M	Forward P/E	-	EPS next Y	-2.18	Insider Trans	-0.02%	Shs Float	106.10M	Perf Month	-19.95%
Income	-354.69M	PEG	-	EPS next Q	-0.52	Inst Own	68.09%	Short Float / Ratio	31.49% / 17.21	Perf Quarter	-36.22%
Sales	0.19M	P/S	2796.77	EPS this Y	3.80%	Inst Trans	4.74%	Short Interest	33.42M	Perf Half Y	-36.22%
Book/sh	3.73	P/B	0.85	EPS next Y	2.11%	ROA	-41.28%	Target Price	17.19	Perf Year	-72.27%
Cash/sh	2.93	P/C	1.08	EPS next 5Y	1.00%	ROE	-49.79%	52W Range	3.28 - 12.21	Perf YTD	-49.60%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-49.63%	52W High	-74.04%	Beta	0.79
Dividend %	-	Quick Ratio	9.18	Sales past 5Y	-19.87%	Gross Margin	-7831.25%	52W Low	-3.35%	ATR	0.22
Employees	361	Current Ratio	9.18	Sales Q/Q	-48.84%	Oper. Margin	-186693.23%	RSI (14)	26.15	Volatility	7.61% 5.51%
Optionable	Yes	Debt/Eq	0.16	EPS Q/Q	-1.86%	Profit Margin	-184733.33%	Rel Volume	1.47	Prev Close	3.41
Shortable	Yes	LT Debt/Eq	0.15	Earnings	Aug 02 AMC	Payout	-	Avg Volume	1.94M	Price	3.17
Recom	1.53	SMA20	-17.36%	SMA50	-24.08%	SMA200	-42.28%	Volume	2,859,345	Change	-7.04%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-26-23	Resumed	Oppenheimer	Outperform	$28
Mar-21-23	Initiated	Bernstein	Mkt Perform	$6
Jan-24-23	Upgrade	JP Morgan	Neutral → Overweight	$20 → $11
Jan-06-23	Upgrade	Robert W. Baird	Neutral → Outperform	$12
Dec-12-22	Downgrade	BofA Securities	Buy → Underperform	$24 → $9
Aug-10-22	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-15-22	Upgrade	Goldman	Neutral → Buy	$9 → $32
Jun-03-22	Initiated	Robert W. Baird	Neutral	$11
Feb-28-22	Reiterated	B. Riley Securities	Buy	$30 → $21
Oct-20-21	Initiated	Cowen	Outperform
Oct-08-21	Downgrade	Stifel	Buy → Hold	$44 → $18
Oct-08-21	Downgrade	Goldman	Buy → Neutral	$71 → $20
Sep-23-21	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-21-21	Resumed	Jefferies	Buy	$53
May-20-21	Upgrade	Truist	Hold → Buy	$34 → $41
May-14-21	Initiated	B. Riley Securities	Buy	$52
Jan-26-21	Upgrade	Stifel	Hold → Buy	$33 → $43
Dec-10-20	Resumed	H.C. Wainwright	Buy	$40
Nov-24-20	Initiated	BofA Securities	Buy	$41
Oct-23-20	Initiated	RBC Capital Mkts	Outperform	$55

Show Previous Ratings

Sep-27-23 09:09AM	Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Sep-25-23 08:45AM	JP Morgan maintains Overweight recommendation on Allogene Therapeutics amid bullish market sentiment (Investing.com)
Sep-05-23 08:30AM	Allogene Therapeutics Announces Participation in September Investor Conference (GlobeNewswire)
Aug-29-23 07:30AM	16 Most Shorted Stocks Right Now (Insider Monkey)
Aug-23-23 12:26PM	11 Best High Short Interest Stocks To Buy Now (Insider Monkey)
08:44AM	Loading…
Aug-17-23 08:44AM	11 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Aug-14-23 08:30AM	Allogene Therapeutics Appoints Earl Douglas as General Counsel (GlobeNewswire)
Aug-03-23 11:20AM	Allogene's (ALLO) Q2 Loss Narrower Than Expected, Sales Miss (Zacks) +9.59%
Aug-02-23 05:25PM	Allogene Therapeutics (ALLO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:13PM	Allogene Therapeutics: Q2 Earnings Snapshot (AP Finance)
04:02PM	Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
10:41AM	Too Cheap to Ignore: J.P. Morgan Says These 2 Stocks Under $10 Could Double Your Money (TipRanks)
Jul-26-23 08:30AM	Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023 (GlobeNewswire)
Jun-15-23 09:30AM	Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano (GlobeNewswire)
Jun-14-23 08:00AM	Allogene Therapeutics Announces Departure of Chief Financial Officer (GlobeNewswire) -12.54%
06:25PM	Loading…
Jun-09-23 06:25PM	Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano (GlobeNewswire)
08:02AM	12 Best Short Squeeze Stocks to Buy Now (Insider Monkey)
Jun-03-23 09:00AM	Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Jun-02-23 11:31AM	Allogene Therapeutics (ALLO) Down 17.5% Since Last Earnings Report: Can It Rebound? (Zacks) +5.45%
May-31-23 12:02PM	Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal (Zacks)
10:46AM	J&J (JNJ) Submits NDA for Single Tablet Combo to Treat PAH (Zacks)
May-29-23 07:48AM	AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal (Zacks)
May-26-23 10:51AM	Apellis' (APLS) Study on Pegcetacoplan to Treat ALS Fails (Zacks)
09:55AM	Wall Street Analysts See a 210.24% Upside in Allogene Therapeutics (ALLO): Can the Stock Really Move This High? (Zacks)
08:23AM	PDS Biotech (PDSB) Up 32% on Interim Data From HPV Cancer Study (Zacks)
May-25-23 03:16PM	Immutep (IMMP) Up on Initial Data From Lung Cancer Study (Zacks)
May-24-23 11:37AM	Icosavax (ICVX) Up on Positive VLP Vaccine Candidate Data (Zacks) -5.95%
08:30AM	Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences (GlobeNewswire)
08:14AM	INOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock Up (Zacks)
May-22-23 08:16AM	We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully (Simply Wall St.)
11:16AM	Loading…
May-19-23 11:16AM	PDS Biotech (PDSB) Completes Enrollment for HPV Cancer Study (Zacks)
10:24AM	AbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease (Zacks)
May-18-23 04:37PM	7 Short-Interest Stocks to Target for Explosive Gains (InvestorPlace)
12:45PM	MindMed (MNMD) Up on 50% Enrollment in Anxiety Disorder Study (Zacks)
11:15AM	Ultragenyx's (RARE) GTX-102 Gets FDA Nod for Uniform Dosing (Zacks)
May-17-23 02:19PM	Intercept's (ICPT) Liver Drug Combo Gets FDA's Orphan Drug Tag (Zacks)
11:21AM	PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up (Zacks)
11:13AM	Bayer's (BAYRY) Arrhythmia Prevention Drug Gets Fast Track Tag (Zacks)
May-16-23 09:31AM	Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases (Zacks) -9.05%
May-12-23 12:08PM	ImmunoGen (IMGN) Stock Surges 230% in a Month: Here's Why (Zacks)
11:34AM	FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing (Zacks)
10:04AM	Corvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why (Zacks)
May-11-23 12:25PM	Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View (Zacks)
11:50AM	Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress (GlobeNewswire)
09:44AM	Reata (RETA) Q1 Earnings Miss, Stock Dips on Pipeline Updates (Zacks)
09:33AM	TEVA Q1 Earnings Miss Estimates, Sales Beat, Stock Declines (Zacks)
07:44AM	Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Grow (Zacks)
May-10-23 09:55AM	Wall Street Analysts Think Allogene Therapeutics (ALLO) Could Surge 184.59%: Read This Before Placing a Bet (Zacks)
May-09-23 10:40AM	Acadia Pharmaceuticals (ACAD) Q1 Earnings & Sales Miss Estimates (Zacks)
May-08-23 10:04AM	Intra-Cellular (ITCI) Q1 Earnings Top, Caplyta Volume Rises (Zacks)
May-05-23 09:40AM	Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:15AM	Intellia (NTLA) Beats on Q1 Earnings, Gives Pipeline Update (Zacks)
May-04-23 03:29PM	Corcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales Guidance (Zacks) +12.76%
12:04PM	Zoetis (ZTS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y (Zacks)
11:43AM	Q1 2023 Allogene Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
11:43AM	Allogene's (ALLO) Q1 Loss Wider Than Expected, Sales Miss (Zacks)
May-03-23 05:25PM	Allogene Therapeutics (ALLO) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +6.92%
04:02PM	Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update (GlobeNewswire)
01:47PM	Amarin's (AMRN) Q1 Earnings Top, Vascepa Sales Fall (Zacks)
01:20PM	Repligen (RGEN) Beats on Q1 Earnings, Lowers 2023 Guidance (Zacks)
May-02-23 11:12AM	Should You Buy Allogene Therapeutics (ALLO) Ahead of Earnings? (Zacks)
Apr-27-23 10:02AM	AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-26-23 10:06AM	Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
10:02AM	Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-25-23 08:30AM	Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023 (GlobeNewswire)
Apr-24-23 09:55AM	Wall Street Analysts Believe Allogene Therapeutics (ALLO) Could Rally 278.19%: Here's is How to Trade (Zacks)
02:06AM	Allogene Therapeutics (ALLO) Surges 8.4%: Is This an Indication of Further Gains? (Zacks)
Apr-20-23 04:05PM	Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer (GlobeNewswire)
Apr-19-23 01:53PM	Here's Why You Should Add Allogene (ALLO) Stock to Your Portfolio (Zacks)
Apr-17-23 10:15AM	Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Apr-14-23 01:53PM	Alvotech (ALVO) Declines on CRL for Humira's Biosimilar Candidate (Zacks)
Apr-13-23 03:12PM	7 Short-Squeeze Stocks That Could Make You Rich (InvestorPlace) +10.02%
08:30AM	Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences (GlobeNewswire)
Mar-31-23 09:35AM	Here's Why Allogene Therapeutics (ALLO) is Poised for a Turnaround After Losing -17.44% in 4 Weeks (Zacks)
Mar-30-23 02:07PM	7 Short-Squeeze Stocks That Could Explode in April (InvestorPlace)
11:30AM	Why Is Allogene Therapeutics (ALLO) Down 19.4% Since Last Earnings Report? (Zacks)
08:30AM	Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report (GlobeNewswire)
Mar-14-23 05:30PM	Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-10-23 12:12PM	Roche (RHHBY) Polivy Combo Backed by FDA Advisory Committee (Zacks)
Mar-09-23 10:21AM	Trevena (TRVN) Initiates Proof-of-Concept for Epilepsy Candidate (Zacks)
Mar-07-23 09:55AM	Allogene Therapeutics (ALLO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Mar-06-23 12:33PM	KALA Q4 Loss Wider Than Expected, Pipeline Remains in Focus (Zacks)
11:56AM	Bristol Myers (BMY) Gets EU Nod for Anemia Drug Reblozyl (Zacks)
09:35AM	After Plunging -23.01% in 4 Weeks, Here's Why the Trend Might Reverse for Allogene Therapeutics (ALLO) (Zacks)
Mar-03-23 02:20PM	Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top (Zacks)
11:40AM	15 Most Shorted Stocks Right Now on Wall Street (Insider Monkey)
Mar-02-23 11:44AM	Jazz's (JAZZ) Q4 Earnings Miss Estimates, New Drugs Drive Sales (Zacks) -5.05%
08:43AM	Horizon's (HZNP) Q4 Earnings and Revenues Surpass Estimates (Zacks)
08:30AM	Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences (GlobeNewswire)
05:12AM	Allogene Therapeutics Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Mar-01-23 11:02AM	Sarepta (SRPT) Q4 Earnings & Sales Beat Estimates, Stock Up (Zacks)
09:36AM	Allogene (ALLO) Incurs Narrower-Than-Expected Loss in Q4 (Zacks)
09:27AM	Q4 2022 Allogene Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
08:30AM	Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy (GlobeNewswire)
Feb-28-23 05:15PM	Allogene Therapeutics (ALLO) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:02PM	Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
11:11AM	Perrigo (PRGO) Beats Q4 Earnings Estimates, Lags on Sales (Zacks)
Feb-27-23 09:31AM	Drug, Biotech Stocks' Q4 Earnings on Feb 28: NVAX, IOVA & More (Zacks)
Feb-24-23 11:52AM	Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q4 (Zacks)
Feb-21-23 08:30AM	Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023 (GlobeNewswire) -7.22%

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mayo Stephen	Director	Aug 07	Sale	4.29	10,000	42,855	25,328	Aug 09 04:07 PM
Bhavnagri Veer	General Counsel	Feb 13	Sale	6.85	3,000	20,550	577,677	Feb 14 05:10 PM
Bhavnagri Veer	General Counsel	Jan 17	Sale	7.04	3,000	21,120	580,677	Jan 18 06:10 PM
Bhavnagri Veer	General Counsel	Dec 15	Sale	7.53	5,602	42,186	583,677	Dec 19 04:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALLO | Allogene Therapeutics Inc

Upgrade your FINVIZ experience